1.. INTRODUCTION
================

Lung cancer is one of the most common causes of cancer mortality in both men and women worldwide [@b1-conc17-1-33]. Most patients develop non-small-cell lung cancer ([nsclc]{.smallcaps}) and have either locally advanced or metastatic disease at presentation. Previous surveys conducted in 1993 and 1995 revealed wide variations in the treatment policies of Canadian radiation oncologists for [nsclc]{.smallcaps}, and those surveys concluded that personal beliefs, rather than universal knowledge, tended to guide the management of [nsclc]{.smallcaps} in Canada [@b2-conc17-1-33],[@b3-conc17-1-33].

In the 13 years since the more recent of the two surveys, the results of several randomized clinical trials focusing on palliative radiotherapy ([rt]{.smallcaps}) for locally advanced and metastatic [nsclc]{.smallcaps} have been published [@b4-conc17-1-33]--[@b12-conc17-1-33]. However, the optimal dose, fractionation scheme, and timing for palliative [rt]{.smallcaps} in [nsclc]{.smallcaps} remain controversial. The present study was undertaken to determine current patterns of practice across Canada for locally advanced and metastatic [nsclc]{.smallcaps} and to establish whether practice actually changed in the preceding decade.

The study survey consisted of three case scenarios designed to question radiation oncologists on areas of [nsclc]{.smallcaps} treatment in which the [rt]{.smallcaps} regimen that provides the best therapeutic ratio is unclear ([Table I](#tI-conc17-1-33){ref-type="table"}).

2.. MATERIALS AND METHODS
=========================

An online survey was distributed electronically to all active members of the Canadian Association of Radiation Oncologists (*n* = 274) in March 2007; those treating lung cancer were invited to participate. The study was approved by the Research Ethics Board at the University Health Network (Toronto, ON).

The initial page of the online survey required the explicit consent of study participants before the survey started. Respondents were presented with the three case scenarios listed in [Table I](#tI-conc17-1-33){ref-type="table"}. For each scenario, they were asked to specify the treatment regimen they would use, details pertaining to treatment delivery, and the effect that the treatment might potentially have on patient survival. In addition, non-identifying demographic information was solicited: the location and year in which respondents completed their specialty training, their current location and type of practice, and their level of experience in treating lung cancer. Finally, respondents were asked to rank the effect of each of the following factors on their treatment decisions: journals and books, seminars and meetings, practice guidelines, departmental policy, colleague preferences and expert opinions, personal experience, and availability of open clinical trials.

Responses were collected as either the single best answer or all applicable answers (chosen from menu options) and as free text. Percentages of respondents selecting a specific option were calculated. Statistical comparisons were made using contingency tables, generally with a chi-square test, using a Yates correction when required. When answer groups included fewer than 20 respondents or fewer than 5 events, the Fisher exact test was employed. Logistic regression was used to identify demographic factors associated with the treatment choice in each case. All tests of significance were two-sided, and differences were considered statistically significant at *p* values below 0.05. The SPSS software application (version 14: SPSS, Chicago, IL, U.S.A.) was used for all analyses.

3.. RESULTS
===========

3.1. Overview
-------------

Of the 46 responses collected, 41 were sufficiently complete and suitable for analysis; 5 were incomplete (\>95% of questions unanswered) and were therefore excluded. This sample represented responses from 23 of 37 Canadian cancer centres and from approximately 30%--40% of the radiation oncologists treating lung cancer in Canada, based on a previous survey that identified 103 radiation oncologists treating lung cancer patients in Canada [@b13-conc17-1-33] and estimating that that number had grown by 10%--20% in the intervening period. All regions of the country were well represented. The distribution of respondents by centres showed 1 respondent from each of 15 centres, 2 respondents from 4 centres, 3 respondents from 1 centre, 4 respondents from 1 centre, and 5 respondents from 2 centres. [Table II](#tII-conc17-1-33){ref-type="table"} summarizes demographic data for the respondents.

3.2. Scenario A: Asymptomatic Patient with Stage IIIB NSCLC Unsuitable for Radical Treatment
--------------------------------------------------------------------------------------------

### 3.2.1. Radiotherapy Plan

For an asymptomatic patient with stage [iiib nsclc]{.smallcaps} unsuitable for radical treatment, 22% of respondents recommended immediate [rt]{.smallcaps}, and 78% recommended [rt]{.smallcaps} only if the patient became symptomatic ([Table III](#tIII-conc17-1-33){ref-type="table"}). Of respondents choosing immediate [rt]{.smallcaps}, all but 1 (89%) aimed to prevent symptoms ([Table IV](#tIV-conc17-1-33){ref-type="table"}). In all instances, computed tomography ([ct]{.smallcaps}) simulation was chosen. All respondents but 1 (89%) chose an anterior--posterior parallel pair ([ap]{.smallcaps}/[pa]{.smallcaps}) plan over a three-dimensional (3D) conformal plan. Three dose fractionation schedules were prescribed: 20 Gy in 5 fractions over 1 week (4 respondents); 30 Gy in 10 fractions over 2 weeks (3 respondents); and 60 Gy in 30 fractions over 6 weeks (1 respondent). One respondent did not specify a dose--fractionation scheme. Half the respondents predicted that the average wait time for the start of [rt]{.smallcaps} treatment (once the decision to treat was made) would be less than 1 week. Respondents in departments with wait times exceeding 1 week were more likely to chose a shorter fractionation schedule (*p* = 0.029).

### 3.2.2. Prognosis and Effect of Treatment

A majority of respondents (61%) estimated the median survival of the patient in scenario A to be 6--12 months ([Table IV](#tIV-conc17-1-33){ref-type="table"}). Only 27% of the respondents believed that immediate [rt]{.smallcaps} (versus delayed [rt]{.smallcaps} until needed to treat symptoms) would prolong survival. Those who believed that immediate [rt]{.smallcaps} would prolong survival were more likely to recommend it (*p* = 0.028).

3.3. Scenario B: Patient with Bulky, Unresectable Stage IIIB NSCLC and Good Performance Status
----------------------------------------------------------------------------------------------

### 3.3.1. Radiotherapy Plan

For a patient with a bulky, stage [iiib]{.smallcaps} tumour and good performance status ([ps]{.smallcaps}), 39% of respondents recommended palliative treatment, and 61% recommended radical treatment ([Table IV](#tIV-conc17-1-33){ref-type="table"}). Most respondents (76%) recommended combined chemoradiation, and 20% recommended [rt]{.smallcaps} alone ([Table III](#tIII-conc17-1-33){ref-type="table"}). Those who chose radical chemoradiation preferred a concurrent over a sequential approach (84% vs. 16%). A dose range of 60--66 Gy in 30--33 fractions was prescribed by all respondents but 1 (who recommended radical treatment, [Table V](#tV-conc17-1-33){ref-type="table"}). For palliative treatment, the most frequently prescribed dose was 30 Gy in 10 fractions over 2 weeks. Overall, 54% of the respondents aimed to prolong survival; 37%, to relieve symptoms; 7%, to prevent symptoms; and 2%, to "provide local control" ([Table IV](#tIV-conc17-1-33){ref-type="table"}). Respondents who aimed primarily to relieve symptoms selected a lower dose and a shorter fractionation schedule (*p* \< 0.001). Simulation by [ct]{.smallcaps} was chosen over fluoroscopic simulation by all respondents but 1. The most commonly chosen plan was a 3D conformal plan (56%), with 31% of the respondents electing to use an [ap]{.smallcaps}/[pa]{.smallcaps} plan, and the remaining 13% choosing an oblique or other plan (unspecified). A majority of respondents (59%) predicted that the average wait time for starting [rt]{.smallcaps} treatment would be 1--2 weeks.

### 3.3.2. Prognosis and Effect of Treatment

Of the survey respondents, 59% estimated the median survival of the patient in scenario B to be 6--12 months ([Table IV](#tIV-conc17-1-33){ref-type="table"}). A preponderance believed that treatment would prolong survival (88% stated that [rt]{.smallcaps} would prolong survival, 64% that chemotherapy would, and 93% that chemoradiation would). Respondents who recommended radical treatment or chemoradiation (as compared with those who did not) indicated a greater effect for chemoradiation on survival (*p* \< 0.001).

3.4. Scenario C: Symptomatic Stage IV Patient with Poor Performance Status
--------------------------------------------------------------------------

### 3.4.1. Radiotherapy Plan

For a symptomatic patient with stage [iv nsclc]{.smallcaps}, 54% recommended external-beam [rt]{.smallcaps} ([ebrt]{.smallcaps}) alone, 10% recommended endobronchial therapy followed by [ebrt]{.smallcaps}, 5% recommended brachytherapy followed by [ebrt]{.smallcaps}, 2% recommended brachytherapy alone, 24% recommended [ebrt]{.smallcaps} followed by chemotherapy, and 5% recommended best supportive care ([Table III](#tIII-conc17-1-33){ref-type="table"}). All respondents aimed to relieve symptoms. Most (82%) chose [ct]{.smallcaps} simulation over fluoroscopic simulation (18%), and an [ap]{.smallcaps}/[pa]{.smallcaps} plan (95%) over a 3D conformal plan (5%). Five dose--fractionation schedules for [ebrt]{.smallcaps} were prescribed (*n* = 38): 20 Gy in 5 fractions over 1 week (76%); 30 Gy in 10 fractions over 2 weeks (13%); 36 Gy in 12 fractions over 2.5 weeks (8%); and 17 Gy in 2 fractions over 1 week (3%). Each respondent who chose brachytherapy prescribed a different dose: 8 Gy every week for 3 weeks, and single 10-Gy and single 20-Gy fractions. Most respondents (79%) predicted that the average wait time for [rt]{.smallcaps} treatment start would be less than 1 week ([Table IV](#tIV-conc17-1-33){ref-type="table"}). Respondents in departments with wait times exceeding 1 week tended to chose a shorter fractionation schedule (*p* = 0.016).

### 3.4.2. Prognosis and Effect of Treatment

Most respondents (71%) estimated the median survival of the patient in scenario C to be less than 6 months, and none felt that it would be longer than 18 months ([Table IV](#tIV-conc17-1-33){ref-type="table"}). Almost one third of the respondents (32%) believed that [rt]{.smallcaps} would prolong survival; 66%, that chemotherapy would prolong survival; and 51%, that chemoradiation would prolong survival. Respondents who recommended chemotherapy (as compared with those who did not) indicated a greater effect for chemotherapy on survival (*p* \< 0.001).

3.5. Correlation with Demographic Factors
-----------------------------------------

We also examined demographic factors of the respondents possibly associated with treatment choice in each case: the year specialty training was completed, the location of residency or fellowship training, number of years dealing with lung cancer, location of practice, type of practice, and number of new [nsclc]{.smallcaps} patients seen annually.

In scenario A, radiation oncologists in the community were more likely than those in university-affiliated centres to recommend immediate [rt]{.smallcaps} (*p* = 0.011). In scenario B, radiation oncologists who had finished training more recently and those who saw more patients per year were more likely to recommend radical treatment (*p* = 0.017 and *p* = 0.010 respectively). We observed no correlations between treatment choice and demographic factors in scenario C.

When asked to rank the effect of 7 factors with respect to treatment decisions, 17 respondents chose practice guidelines as the most important, 9 chose availability of open clinical trials, 4 chose departmental policy, 4 chose journals and books, 3 chose seminars and meetings, 3 chose personal experience, and 1 chose colleague preferences and expert opinions. "Practice guidelines" were ranked by 80% of the respondents as one of the three most important factors influencing their treatment decisions; "personal experience" was ranked as one of the three most important factors by 52%.

4.. DISCUSSION
==============

Palliative [rt]{.smallcaps} regimens in advanced [nsclc]{.smallcaps} have been subject to rigorous evaluation in clinical trials [@b4-conc17-1-33]--[@b12-conc17-1-33],[@b14-conc17-1-33]. However, the way in which radiation oncologists interpret the results of these trials influences their treatment recommendations. The present study explored current patterns of practice for locally advanced and metastatic [nsclc]{.smallcaps} in Canada. Our survey had an estimated response rate of approximately 30%--40%. Although limited, our response rate is higher than that in other similar studies [@b15-conc17-1-33],[@b16-conc17-1-33]. A precise response rate cannot be provided, because it is difficult to determine the exact number of radiation oncologists who were treating lung cancer in Canada at the time of the survey. A better way to investigate patterns of practice across a nation is through practice audit; however, that approach is time consuming and often impractical. As a result, many studies, including ours, use survey data as a surrogate. One potential limitation is that survey data may not accurately represent what is done in actual practice.

With advancements in technology, changes have occurred in how palliative [rt]{.smallcaps} is delivered. Our survey confirmed these changes. In all three cases, [ct]{.smallcaps} simulation was used by most respondents (82%-- 100%). However, for "palliative" cases (scenarios A and C), [ap]{.smallcaps}/[pa]{.smallcaps} was preferred over a conformal plan (89%--95%). That finding is consistent with an [ap]{.smallcaps}/[pa]{.smallcaps} plan being unlikely to exceed spinal cord tolerance for palliative cases, but not for radical cases.

For minimally symptomatic patients with unresectable [nsclc]{.smallcaps} not suitable for radical treatment (such as in scenario A), a randomized trial published in 2002 showed that immediate [rt]{.smallcaps} does not improve symptom control, quality of life, or survival when compared with delay until symptoms require treatment [@b17-conc17-1-33]. The median survival of patients in this trial by Falk *et al.* were 8.3 months (immediate [rt]{.smallcaps}) and 7.9 months (delayed [rt]{.smallcaps}---most did not receive [rt]{.smallcaps}). In our study, most respondents estimated the survival of the patient in scenario A to be 6--12 months, which agrees with the published results. Most respondents also believed that immediate [rt]{.smallcaps} would not prolong survival, and 78% chose not to give [rt]{.smallcaps} immediately and to treat only if the patient became symptomatic. When a similar case was presented in a survey conducted in 1995, only 17% of the respondents chose no immediate active treatment [@b3-conc17-1-33]. This change in the reported practice pattern may indeed be attributable to the published evidence. Increased use of chemotherapy may be a factor as well.

Scenario B is the most challenging scenario with respect to knowing the best evidence-based treatment. It was purposely designed to address a specific dilemma: What is the chance of cure for a patient with good [ps]{.smallcaps}, a bulky tumour, and no obvious metastases, if treated with radical chemoradiation rather than high-dose palliative [rt]{.smallcaps}?

Several meta-analyses have shown that chemoradiation improves survival when compared with [rt]{.smallcaps} alone for unresectable stage [iii nsclc]{.smallcaps} (absolute survival benefit of 2 months or 2% at 5 years) [@b18-conc17-1-33]--[@b20-conc17-1-33]. However, the entry criteria for each trial differed, and the trials often do not explicitly state the tumour size, bulk, or intrathoracic disease deemed suitable for radical treatment. Most studies excluded patients based only on their blood work, pulmonary function, weight loss, and performance status (Eastern Cooperative Oncology Group score \>1 or \>2). The patient in scenario B certainly could have been an eligible candidate for randomized trials that investigated radical chemoradiation for unresectable stage [iii nsclc]{.smallcaps}. In most of those trials, the median survival of patients with unresectable stage [iii nsclc]{.smallcaps} who received chemoradiation ranged from 10--18 months, compared with 9--12 months with radiotherapy alone [@b18-conc17-1-33]--[@b20-conc17-1-33], and approximately 8 months with no immediate treatment (reported by Falk *et al.*) [@b17-conc17-1-33]. The estimate of the respondents concerning the effect of chemoradiation on survival for the patient in scenario B varied. However, as in scenario A, the estimate given by most respondents for the median survival of patient B without treatment agrees with the results in the existing literature and is also consistent with their estimates in scenario A. When a case similar to that of the patient in scenario B was presented in a previous survey in 1993 [@b2-conc17-1-33], but with a much smaller tumour (4 cm compared with the 9 cm here) and a younger patient (59 years vs. 72 years), only 31% of the respondents chose a radical approach. In contrast, 61% of the respondents in the present study chose a radical approach despite a much larger tumour (and thus likely a lower chance of cure), and more advanced patient age. Compared with past practice, the practice of today's Canadian radiation oncologists has evolved to favour more aggressive treatment for [nsclc]{.smallcaps}. However, whether this evolving practice is evidence-based is less clear.

Despite numerous studies examining various palliative dose--fractionation regimens, the optimal regimen for a symptomatic patient such the one described in scenario C is not clearly established. The most recent Cochrane review concluded that most patients with locally advanced [nsclc]{.smallcaps} and thoracic symptoms should be treated with short courses of palliative [rt]{.smallcaps}, but selected patients with good [ps]{.smallcaps} should be considered for higher-dose palliative regimens--- for example, 36 Gy in 12 fractions) [@b14-conc17-1-33]. Practice patterns tend to be geographically based, and studies conducted by national groups often influence practice more than do studies undertaken elsewhere. The study most relevant to Canadians is the National Cancer Institute of Canada Clinical Trials Group [sc]{.smallcaps}.15 trial, in which 20 Gy in 5 fractions provided not only a similar degree of palliation of thoracic symptoms but also a 2-month survival advantage as compared with a single fraction of 10 Gy [@b8-conc17-1-33]. On post-hoc subgroup analysis, the improvement persisted only for patients who were [ps]{.smallcaps} 0--1 and had localized disease. Overall, patients who received 20 Gy in 5 fractions experienced significantly greater improvement in symptoms related to lung cancer, pain, and ability to carry out normal activities and a better global quality of life.

In the present survey, for the patient in scenario C with a [ps]{.smallcaps} 2, most respondents (76%) prescribed 20 Gy in 5 fractions using [ebrt]{.smallcaps}, and 71% of those who prescribed 20 Gy in 5 fractions believed that this regimen had no effect on survival, in keeping with results from the Canadian study. A majority of respondents (66%) also believed that chemotherapy had some effect on survival, and 24% chose [ebrt]{.smallcaps} followed by chemotherapy. Those numbers are similar to the numbers obtained in the previous survey (60% and 20% respectively). However, it is hard to make a direct comparison, because the patient in the present scenario is considerably older and has a poorer [ps]{.smallcaps} and more medical co-morbidities. For patients with a good [ps]{.smallcaps}, the meta-analysis from 1996 showed that, as compared with best supportive care, chemotherapy is associated with improved quality of life and survival (5--7.5 months vs. 4 months) [@b19-conc17-1-33]. This meta-analysis is being updated, and the benefit of chemotherapy is expected to be even greater now with third-generation regimens.

Data are also available to support the use of single-agent chemotherapy in elderly patients, or patients with a [ps]{.smallcaps} of 2 [@b21-conc17-1-33],[@b22-conc17-1-33], but the evidence is not abundant for elderly patients with a [ps]{.smallcaps} of 2 because they are often underrepresented in clinical trials [@b23-conc17-1-33]. In the present study, most respondents (71%) estimated the median survival of the patient in scenario C to be less than 6 months, and they believed that chemotherapy would provide a survival benefit of less than 3 months, in keeping with the available evidence. Only 1 respondent chose brachytherapy alone, because there is evidence that high dose rate ([hdr]{.smallcaps}) brachytherapy alone is less effective than [ebrt]{.smallcaps} alone [@b24-conc17-1-33],[@b25-conc17-1-33]. Existing evidence does not conclusively indicate that [hdr]{.smallcaps} brachytherapy and [ebrt]{.smallcaps} would provide improved symptom relief over [ebrt]{.smallcaps} alone, and only 2 respondents (5%) chose brachytherapy with [ebrt]{.smallcaps} [@b24-conc17-1-33].

Endobronchial therapy followed by [ebrt]{.smallcaps} was chosen by 4 respondents (10%). Although the role of endobronchial therapy such as photodynamic therapy is not well defined, it can contribute to symptom relief. One randomized trial showed significant improvement in the control of hemoptysis and the relief of dyspnea for patients receiving photodynamic therapy plus [rt]{.smallcaps} as compared with those receiving [rt]{.smallcaps} alone [@b26-conc17-1-33]. For scenario C, most of the recommendations are in keeping with available evidence.

Overall, most Canadian radiation oncologists appear to practice evidence-based medicine, because their regimens are in agreement with results of several randomized studies. However, as in the preceding decade [@b3-conc17-1-33], the beliefs of the radiation oncologists about the treatment's effect on survival still vary and also influence treatment decisions. For each scenario in the present study, radiation oncologists were more likely to recommend the treatment that they believed would have the greater impact on survival. Survival benefits may be overestimated by some of the respondents. The effect of the beliefs of the oncologists was also illustrated by Graham *et al.*, who found that the attitudes of Ontario oncologists toward practice guidelines correlated with their intention to use those guidelines [@b27-conc17-1-33]. Therefore, if strategies aiming to increase the uptake of evidence into practice are to be useful, they need to address those beliefs and perceptions.
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###### 

Three case scenarios of non-small-cell lung cancer ([nsclc]{.smallcaps}) presented in the survey

  -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Scenario A*   *Should patients with locally advanced*[nsclc]{.smallcaps}*unsuitable for resection or radical radiotherapy, and with no or minimal thoracic symptoms, be given palliative radiotherapy (*[rt]{.smallcaps}*) immediately or as needed to treat symptoms?*\
                 An 80-year-old man with chronic obstructive pulmonary disease and chronic renal failure is found to have a 4-cm mass in the right upper lobe on routine chest radiograph. Biopsy of the mass confirms the diagnosis of squamous cell carcinoma ([scc]{.smallcaps}). Mediastinoscopy reveals bilateral mediastinal lymph node involvement with [scc]{.smallcaps}. The rest of the metastatic workup is negative. Aside from fatigue, the patient has only a minor chronic cough, an Eastern Cooperative Oncology Group score of 2, and 14% weight loss within the past 6 months.

  *Scenario B*   *Should patients with unresectable stage*[iii nsclc]{.smallcaps}*and large tumour volume be considered for radical treatment?*\
                 A 72-year-old previously healthy woman presents with a 2-week history of minor hemoptysis and no other symptoms. Her chest radiograph shows a 9-cm mass in the right upper lobe and associated partial atelectasis. Biopsy of the mass confirmsthe diagnosis of squamous cell carcinoma ([scc]{.smallcaps}). Mediastinoscopy reveals bilateral bulky mediastinal lymph node involvement with [scc]{.smallcaps}, and the rest of the metastatic workup is negative. Her forced expiratory volume in 1 s is 2 L (80% of predicted). She has mild fatigue, an Eastern Cooperative Oncology Group score of 1--2, and 3% weight loss within the past 3 months.

  *Scenario C*   *For symptomatic patients with metastatic*[nsclc]{.smallcaps}*, which dose--fractionation regimen is most appropriate?*\
                 A 70-year-old man presents with worsening dyspnea and no other symptoms. Computed tomography imaging of the chest shows a mass measuring approximately 4 cm and associated right middle lobe ([rml]{.smallcaps}) atelectasis. Bronchoscopy reveals the mass to be almost completely obstructing the diagnosis the [rml]{.smallcaps} bronchus, and biopsy of the mass confirms of squamous cell carcinoma. Bone scan shows 2 foci of metastatic deposits in the spine, which are asymptomatic. The patient has multiple co-morbidities, including diabetes and coronary artery disease, and has an Eastern Cooperative Oncology Group score of 2--3 and 12% weight loss within the past 6 months.
  -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of the survey respondents

  Characteristic                                                      Respondents   
  ------------------------------------------------------------------- ------------- -----
  All respondents                                                     41            100
  Year specialty training completed                                                 
   1970--1979                                                         1             2
   1980--1989                                                         8             20
   1990--1999                                                         18            44
   2000 and after                                                     14            34
  Location of specialty training                                                    
   Canada                                                             38            93
   Britain                                                            3             7
  Fellowship training                                                               
   Yes                                                                28            68
   No                                                                 13            32
  Location of fellowship training                                                   
   Canada                                                             17            61
   United States                                                      7             25
   Britain or Ireland                                                 2             7
   France                                                             2             7
  Years treating lung cancer                                                        
   ≤5                                                                 12            29
   6--10                                                              15            37
   10--20                                                             11            27
   20--30                                                             3             7
  Locally advanced or metastatic [nsclc]{.smallcaps} cases annually                 
   ≤20                                                                4             10
   21--50                                                             9             22
   51--100                                                            16            39
   \>100                                                              12            29
  Practice setting                                                                  
   University-affiliated                                              32            78
   Community-based                                                    9             22
  Geographic location                                                               
   Western Canada                                                     9             22
   Ontario                                                            21            51
   Quebec                                                             6             15
   Atlantic Canada                                                    5             12

###### 

Treatment recommendation for the case scenarios presented in [Table I](#tI-conc17-1-33){ref-type="table"} (*N* = 41)

  Scenario     Respondents                                                                                   
  ------------ --------------------------------------- ------------------------------------------------ ---- ----
  Scenario A   Asymptomatic stage [iiib]{.smallcaps}   Immediate [rt]{.smallcaps}                       9    22
                                                       Delayed [rt]{.smallcaps}                         32   78
  Scenario B   Bulky stage [iiib]{.smallcaps}          [rt]{.smallcaps}, then chemotherapy              4    10
                                                       Chemotherapy, then [rt]{.smallcaps}              5    12
                                                       Concurrent chemoradiation                        22   54
                                                       [rt]{.smallcaps} alone                           8    20
                                                       Chemotherapy alone                               1    2
                                                       Best supportive care                             1    2
  Scenario C   Symptomatic stage [iv]{.smallcaps}      [ebrt]{.smallcaps}                               22   54
                                                       Brachytherapy                                    1    2
                                                       Brachytherapy, then [ebrt]{.smallcaps}           2    5
                                                       Endobronchial therapy, then [ebrt]{.smallcaps}   4    10
                                                       [ebrt]{.smallcaps}, then chemotherapy            10   24
                                                       Best supportive care                             2    5

[rt]{.smallcaps} = radiation therapy; [ebrt]{.smallcaps} = external-beam [rt]{.smallcaps}.

###### 

Management and perceptions for the three case scenarios presented in [Table I](#tI-conc17-1-33){ref-type="table"}

  Variable                                                              Responses \[*n/N* (%)\]                                                                                       
  --------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------- ------------------
  Treatment intent                                                                                                                                                                    
   Radical                                                              [na]{.smallcaps}                                      25/41 (61)                                              [na]{.smallcaps}
   Palliative                                                           [na]{.smallcaps}                                      16/41 (39)                                              [na]{.smallcaps}
  Aim                                                                                                                                                                                 
   Prolong survival                                                     ---                                                   22/41 (54)                                              ---
   Prevent symptoms                                                     8/9 (89)                                              3/41 (7)                                                ---
   Relieve symptoms                                                     1/9 (11)                                              15/41 (37)                                              41/41 (100)
   Other                                                                ---                                                   1/41 (2)                                                ---
  Estimated wait time from decision to [rt]{.smallcaps} start (weeks)                                                                                                                 
   \>1                                                                  4/8 (50)[a](#tfn2-conc17-1-33){ref-type="table-fn"}   5/39 (13)                                               8/39 (21)
   1--2                                                                 3/8 (38)                                              23/39 (59)                                              16/39 (41)
   2--4                                                                 1/8 (13)                                              10/39 (26)                                              14/39 (36)
   \>4                                                                  ---                                                   1/39 (3)                                                1/39 (3)
  Median survival (months)                                                                                                                                                            
   \<6                                                                  11/41 (27)                                            12/41 (29)                                              29/41 (71)
   6--12                                                                25/41 (61)                                            24/41 (59)                                              11/41 (27)
   12--18                                                               4/41 (10)                                             4/41 (10)                                               1/41 (2)
   \>18                                                                 1/41 (2)                                              1/41 (2)                                                ---
  Impact on median survival (months)                                                                                                                                                  
   [rt]{.smallcaps}                                                                                                                                                                   
    None                                                                30/41 (73)                                            5/39 (13)[b](#tfn3-conc17-1-33){ref-type="table-fn"}    28/41 (68)
    \<3                                                                 7/41 (17)                                             24/39 (62)                                              12/41 (29)
    3--6                                                                4/41 (10)                                             10/39 (26)                                              1/41 (2)
   Delayed [rt]{.smallcaps}                                                                                                                                                           
    None                                                                31/41 (78)                                            [na]{.smallcaps}                                        [na]{.smallcaps}
    \<3                                                                 8/41 (20)                                             [na]{.smallcaps}                                        [na]{.smallcaps}
    3--6                                                                1/41 (2)                                              [na]{.smallcaps}                                        [na]{.smallcaps}
   Chemotherapy                                                                                                                                                                       
    None                                                                [na]{.smallcaps}                                      14/39 (36)[b](#tfn3-conc17-1-33){ref-type="table-fn"}   14/41 (34)
    \<3                                                                 [na]{.smallcaps}                                      19/39 (49)                                              24/41 (59)
    3--6                                                                [na]{.smallcaps}                                      6/39 (15)                                               3/41 (7)
   Chemoradiation                                                                                                                                                                     
    None                                                                [na]{.smallcaps}                                      3/41 (7)                                                20/41 (49)
    \<3                                                                 [na]{.smallcaps}                                      9/41 (22)                                               16/41 (39)
    3--6                                                                [na]{.smallcaps}                                      13/41 (32)                                              4/41 (10)
    \>6                                                                                                                       16/41 (39)                                              1/41 (2)

No answer from 1 respondent.

No answer from 2 respondents.

[rt]{.smallcaps} = radiation therapy.

###### 

Radiotherapy dose and fractionation for the case presented as Scenario B in [Table I](#tI-conc17-1-33){ref-type="table"}[a](#tfn5-conc17-1-33){ref-type="table-fn"}

  Respondents (n)   Dose and fractionation (Gy / fractions / weeks)   Stated intent
  ----------------- ------------------------------------------------- ---------------
  2                 20 / 5 / 1                                        Palliative
  7                 30 / 10 / 2                                       Palliative
  1                 36 / 13 / 2.5                                     Palliative
  2                 40 / 15 / 3                                       Palliative
  1                 50 / 20 / 4                                       Palliative
  1                 50 / 25 / 5                                       Radical
  11                60 / 30 / 6                                       1 Palliative
                                                                      10 Radical
  11                66 / 33 / 6.5                                     Radical
  1                 60--66 / 30--33 / 6--6.5                          Radical
  1                 63 / 34 / 7                                       Radical

Concurrent chemoradiation was chosen by 1 respondent, but the dose was not specified.
